Exposure to guideline-recommended quadruple therapy after first hospitalization for HFrEF in France
Abstract
Introduction: In 2021, the European Society of Cardiology updated its guidelines for managing heart failure with reduced left ventricular ejection fraction (HFrEF), recommending a four-drug regimen combining a sodium-glucose cotransporter 2 (SGLT2) inhibitor, a beta-blocker, a mineralocorticoid receptor antagonist, and a renin–angiotensin–aldosterone system inhibitor. This study assessed, 6 months after guideline publication, the exposure of this quadruple therapy in patients newly hospitalized for HFrEF and identified associated factors.
Methods and results: First-time hospitalizations for HFrEF in France in 2022 were identified using the French National Health Data System. Treatment exposure during the year following discharge was described. Logistic regression was used to assess factors associated with receiving quadruple therapy within 30 days, including socio-demographic characteristics, healthcare utilization, and comorbidities. A total of 22 990 patients were included (65.1% men; mean age 74 years, SD 13.5). At 30 days, 26.3% of patients received quadruple therapy (22.5% at 1 year). Exposure rates were 76% for beta-blockers, 70% for renin–angiotensin–aldosterone system inhibitor, 58% for SGLT2 inhibitors, and 47% for mineralocorticoid receptor antagonists. Advanced age, female sex, and certain comorbidities were associated with a lower likelihood of receiving quadruple therapy, while early follow-up with a general practitioner or cardiologist increased this likelihood.
Discussion: Exposure of quadruple therapy remains limited, with challenges in both initiation and persistence over time. Older age and comorbidities would appear to constitute barriers. Further studies with longer follow-up after guideline publication are needed to assess temporal trends and the impact of strategies aimed at improving care.
Related
- Managing Pediatric Acquired Hemophilia A When Guideline-Recommended Bypassing Agents Are Unavailable: A Case Report
- Effectiveness of Discrete Strategies and Implementation Bundles for Improving Clinician Prescription of Clinical Practice Guideline–Recommended Medications for Atherosclerotic Occlusive Disease: A Systematic Review and Meta‐Analysis
- Automated, Component-Level Assessment of a National Inpatient Diabetes Guideline: Adherence and Its Association with Hospitalization Complications Across Six Hospitals
- Association of individual exposure to PM2.5 components with pulmonary tuberculosis hospitalization and the effect modification by greenness
- Vericiguat for heart failure with reduced ejection fraction on quadruple therapy without recent worsening heart failure: an exploratory real-world cohort study
BibTeX
@article{marqueyssat2026exposure,
title = {{Exposure to guideline-recommended quadruple therapy after first hospitalization for HFrEF in France}},
author = {Gaël-Sean Marqueyssat and Audrey Dintilhac and Olivier Toulza and Philippe Cestac and Blandine Juillard-Condat},
journal = {European Heart Journal Open},
year = {2026},
month = sep,
doi = {10.1093/ehjopen/oeag159},
url = {https://doi.org/10.1093/ehjopen/oeag159},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Exposure to guideline-recommended quadruple therapy after first hospitalization for HFrEF in France
AU - Gaël-Sean Marqueyssat
AU - Audrey Dintilhac
AU - Olivier Toulza
AU - Philippe Cestac
AU - Blandine Juillard-Condat
PY - 2026
DA - 2026/09/25
JO - European Heart Journal Open
DO - 10.1093/ehjopen/oeag159
UR - https://doi.org/10.1093/ehjopen/oeag159
AB - Introduction: In 2021, the European Society of Cardiology updated its guidelines for managing heart failure with reduced left ventricular ejection fraction (HFrEF), recommending a four-drug regimen combining a sodium-glucose cotransporter 2 (SGLT2) inhibitor, a beta-blocker, a mineralocorticoid receptor antagonist, and a renin–angiotensin–aldosterone system inhibitor. This study assessed, 6 months after guideline publication, the exposure of this quadruple therapy in patients newly hospitalized for HFrEF and identified associated factors. Methods and results: First-time hospitalizations for HFrEF in France in 2022 were identified using the French National Health Data System. Treatment exposure during the year following discharge was described. Logistic regression was used to assess factors associated with receiving quadruple therapy within 30 days, including socio-demographic characteristics, healthcare utilization, and comorbidities. A total of 22 990 patients were included (65.1% men; mean age 74 years, SD 13.5). At 30 days, 26.3% of patients received quadruple therapy (22.5% at 1 year). Exposure rates were 76% for beta-blockers, 70% for renin–angiotensin–aldosterone system inhibitor, 58% for SGLT2 inhibitors, and 47% for mineralocorticoid receptor antagonists. Advanced age, female sex, and certain comorbidities were associated with a lower likelihood of receiving quadruple therapy, while early follow-up with a general practitioner or cardiologist increased this likelihood. Discussion: Exposure of quadruple therapy remains limited, with challenges in both initiation and persistence over time. Older age and comorbidities would appear to constitute barriers. Further studies with longer follow-up after guideline publication are needed to assess temporal trends and the impact of strategies aimed at improving care.
SN - 2752-4191
ER -